Lipodystrophy Clinical Trial
Official title:
Performance and Safety of the Lipo-transfer Cannulas in Patients Underlying Lipofilling Treatment
NCT number | NCT06089759 |
Other study ID # | LIPOTRANSFER |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 30, 2023 |
Est. completion date | April 4, 2024 |
The purpose of this post-market clinical follow up study is to assess the safety and performance of Aesthetic Group cannulas. The study will evaluate the outcome of the Aesthetic Group cannulas range over a period of 1 month after intervention.
Status | Recruiting |
Enrollment | 108 |
Est. completion date | April 4, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient age = 18 years at intervention - Patient who will undergo a lipofilling treatment with at least one cannula of Aesthetic Group - Patient informed of his/her participation and willing to participate in the study. - Patient able to read, write and understand French. Exclusion Criteria: - Patient deprived of freedom, under guardianship/curatorship or placed under judicial protection - Patient unable to follow study procedures - Patient with hematologic abnormalities, prior radiotherapy or chemotherapy - Chronic use of medicines or drugs - Patient with diabetes mellitus - Patient with connective tissue diseases, any type of fat tissue disorder (lipodystrophy) - Patient with bleeding disorders; immune deficits; heart, liver, and kidney insufficiency - Patient with allergies to local anaesthetics - Patient with pacemaker and serious heart rhythm disorders - Pregnant and breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | Clinique Pasteur | Brest | |
France | Clinique Phenicia | Marseille | |
France | Clinique Eiffel | Paris |
Lead Sponsor | Collaborator |
---|---|
Aesthetic Group | EVAMED |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The performance of the cannulas for infiltration, fat harvesting or fat injection. | The success rate of cannulas defined by the capacity to infiltrate, harvest or inject. | D0 (at intervention) | |
Secondary | The surgeon's satisfaction with the procedure | The surgeon satisfaction will be assessed using a 4-point scale (likert scale) at intervention. (Very satisfied, Satisfied, Unsatisfied, Very unsatisfied). Very satisfied is the higher score and outcome. | D0 (at intervention) | |
Secondary | The safety of the cannulas during the intervention (All adverse device effects occurred during the intervention will be summarized) | All adverse device effects occurred during the intervention | D0 (at intervention) | |
Secondary | The safety of the intervention within the 1 month post intervention (All adverse events occurred from the intervention to the 1 month follow-up visit will be summarized) | All adverse events occurred from the intervention to the 1 month follow-up visit | D0 (at intervention) to month 1 | |
Secondary | The usability of the cannulas during the intervention | Usability of the cannulas (easy to fit, …) assessed with a questionnaire (Scale of ease of fitting the cannula) in by the investigator (Very satisfied, Satisfied, Unsatisfied, Very unsatisfied). "Very satisfied" is the best value and outcome. | D0 (at intervention) | |
Secondary | The quality of life | Improvement of QoL score (numeric scale, 0 to 10, 10 is the maximum and the best value, 0 is the minimum value) at 1 month compared with pre-operative visit | At baseline and 1 month follow-up | |
Secondary | The patient's satisfaction at 1 month (binary variable) | The proportion of patients who are satisfied at 1 month (binary variable, yes or no, yes is the best value) | At 1 month | |
Secondary | The surgeon's satisfaction at 1 month | The proportion of patients for whom the surgeon is satisfied at 1 month | At 1 month | |
Secondary | The improvement of skin quality/aesthetic (likert scale) | The proportion of patients where the skin quality/aesthetic is improved at each follow-up visit. (Good improvement, mild improvement, no improvement, worsening, "good improvement" is the best value and outcome, "worsening" is the minimum value) | At 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05419037 -
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
|
||
Recruiting |
NCT03059121 -
The Cleveland Cardiometabolic Cohort
|
||
Completed |
NCT00656175 -
Raltegravir Therapy for Women With HIV and Fat Accumulation
|
Phase 2 | |
Completed |
NCT00202241 -
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
|
N/A | |
Completed |
NCT00006185 -
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
|
Phase 1 | |
Recruiting |
NCT02262832 -
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
|
Phase 3 | |
Completed |
NCT01679197 -
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
|
Phase 2 | |
Completed |
NCT02647853 -
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT00715546 -
Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy
|
Phase 1 | |
Completed |
NCT00069004 -
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
|
N/A | |
Completed |
NCT00025883 -
Leptin to Treat Lipodystrophy
|
Phase 2 | |
Completed |
NCT00001142 -
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
|
N/A | |
Active, not recruiting |
NCT02262806 -
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT02258685 -
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
|
||
Completed |
NCT00192621 -
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
|
Phase 4 | |
Completed |
NCT00006190 -
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
|
Phase 4 | |
Recruiting |
NCT05930106 -
Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management
|
N/A | |
Completed |
NCT00004329 -
Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy
|
N/A | |
Recruiting |
NCT04656054 -
Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
|
||
Completed |
NCT00082628 -
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
|
Phase 3 |